Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?
- PMID: 32634243
- DOI: 10.1093/cid/ciaa878
Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?
Comment in
-
Reply to Sfeir.Clin Infect Dis. 2021 Apr 26;72(8):1485-1486. doi: 10.1093/cid/ciaa881. Clin Infect Dis. 2021. PMID: 32634242 No abstract available.
Comment on
-
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530. Clin Infect Dis. 2020. PMID: 31400759 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
